Pluromed, Inc. develops, manufactures, and markets disposable medical devices based on reverse thermosensitive polymer technology in Europe, Canada, and the United States. It offers LeGoo Internal Vessel Occluder, a liquid polymer for the temporary occlusion of blood vessels; and LeGoo Endovascular Occlusion Gel for clampless vascular and cardiovascular surgery. The company also provides BackStop, an atraumatic device to prevent stone migration and stone fragment retropulsion during ureteroscopic lithotripsy; and Lumagel, an oncology product for cancer therapies, partial nephrectomy, hepatic resection, radiofrequency ablation, and chemotherapy. Its products are used to control bleeding during various surgical and interventional procedures including cardiac and vascular surgery, plastic and reconstructive surgery, kidney and liver cancer therapies, and trauma/battlefield injuries. The company was founded in 2003 and is based in Woburn, Massachusetts. As of April 2, 2012, Pluromed, Inc. operates as a subsidiary of Sanofi.